Skip to main content
NVDA-2.39%AAPL+2.31%GOOGL+0.10%MSFT-0.02%AMZN+0.06%TSM-0.72%SPCX+1.69%AVGO-0.04%META+0.40%TSLA-0.45%SKHY-3.99%MU-4.17%BRK-B-0.06%LLY+0.40%JPM-0.38%AMD-2.33%WMT+0.16%V-0.25%XOM-0.26%ASMLa-1.56%JNJ-0.22%INTC-4.20%MA-0.59%0700.HK-1.94%ORCL-2.03%1398.HK+0.79%BAC-0.26%ABBV+0.52%CSCO-0.44%CVX-0.51%COST-0.10%LRCX-3.66%KO+0.59%CAT-0.99%AMAT-2.21%0005.HK-0.78%AP2d-1.57%UNH-0.63%DELL-2.88%HSBA.L-1.01%MS+0.01%PG-0.28%GE+0.11%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.34%HD-1.11%GS-0.18%0939.HK+1.66%NZDJPY-2.68%AUDJPY-1.96%CHFJPY-1.68%USDJPY-1.50%GBPJPY-1.39%EURJPY-1.37%CADJPY-1.36%EURNZD+1.36%NZDCAD-1.34%GBPNZD+1.31%NZDUSD-1.21%NZDCHF-1.04%USDNOK+0.91%EURNOK+0.87%CHFNOK+0.78%AUDNZD+0.75%USDZAR+0.68%USDSEK+0.68%NOKJPY-0.67%EURZAR+0.64%EURSEK+0.64%AUDDKK-0.63%AUDCAD-0.62%EURAUD+0.60%GBPAUD+0.55%GBPZAR+0.55%CHFSEK+0.54%AUDSGD-0.50%AUDUSD-0.46%USDTHB+0.45%USDMXN+0.42%GBPTRY+0.41%NZDSGD-0.32%GBPHKD+0.32%EURCHF+0.31%CADCHF+0.30%GBPMXN-0.28%AUDCHF-0.28%GBPCHF+0.27%USDPLN+0.25%AUDNOK+0.24%EURPLN+0.20%USDCHF+0.19%USDILS+0.16%USDSGD+0.16%EURUSD+0.13%USDCAD-0.12%EURSGD+0.12%GBPUSD+0.11%USDTRY+0.11%EURCZK-0.09%NZDMXN-0.08%SGDJPY+0.07%USDCNH+0.05%EURHKD-0.05%EURGBP+0.04%GBPCAD-0.04%USDCOP-0.04%EURCNH+0.04%USDDKK+0.03%GBPSGD+0.03%CHFSGD+0.03%USDHKD+0.01%PLNJPY-0.01%EURDKK-0.01%EURCAD0.00%XPTUSD-4.74%HG1-4.47%GAGUSD-4.15%XAGUSD-4.14%UKOIL+3.54%USOIL+3.11%SUGAR+1.50%XAUUSD-0.98%GAUUSD-0.98%COFFEE-0.76%COTTON+0.66%S1+0.65%BTCUSD-1.21%ETHUSD-1.02%USDTUSD-0.02%XRPUSD-2.60%SOLUSD-1.48%TRXUSDT0.00%ZECUSDT-5.54%DOGEUSD-2.81%XMRUSDT-1.66%LINKUSD-1.09%XLMUSD-1.92%BCHUSDT-10.38%LTCUSD-1.72%UNIUSD-3.29%TONUSD+24.88%HBARUSDT-1.85%SUIUSD-3.41%TAOUSDT-5.10%AAVEUSD-2.76%DOTUSDT-3.34%ICPUSDT-0.79%ONDOUSDT-2.76%WLDUSDT-2.43%ATOMUSDT-3.35%ARBUSDT+1.64%JUPUSDT-2.96%INJUSDT-4.80%STXUSDT-3.07%FETUSDT-3.57%TIAUSDT-0.87%PYTHUSDT+0.14%SEIUSDT-3.91%IMXUSDT-3.85%GRTUSDT-2.94%WIFUSDT-4.40%OPUSDT-3.00%IOTAUSDT-3.76%POLUSDT-5.71%AXSUSDT-2.47%FARTCOINUSDT-2.75%EOSUSDT-0.93%DYDXUSDT-0.80%ORDIUSDT-0.83%GALAUSDT-4.78%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-2.39%AAPL+2.31%GOOGL+0.10%MSFT-0.02%AMZN+0.06%TSM-0.72%SPCX+1.69%AVGO-0.04%META+0.40%TSLA-0.45%SKHY-3.99%MU-4.17%BRK-B-0.06%LLY+0.40%JPM-0.38%AMD-2.33%WMT+0.16%V-0.25%XOM-0.26%ASMLa-1.56%JNJ-0.22%INTC-4.20%MA-0.59%0700.HK-1.94%ORCL-2.03%1398.HK+0.79%BAC-0.26%ABBV+0.52%CSCO-0.44%CVX-0.51%COST-0.10%LRCX-3.66%KO+0.59%CAT-0.99%AMAT-2.21%0005.HK-0.78%AP2d-1.57%UNH-0.63%DELL-2.88%HSBA.L-1.01%MS+0.01%PG-0.28%GE+0.11%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.34%HD-1.11%GS-0.18%0939.HK+1.66%NZDJPY-2.68%AUDJPY-1.96%CHFJPY-1.68%USDJPY-1.50%GBPJPY-1.39%EURJPY-1.37%CADJPY-1.36%EURNZD+1.36%NZDCAD-1.34%GBPNZD+1.31%NZDUSD-1.21%NZDCHF-1.04%USDNOK+0.91%EURNOK+0.87%CHFNOK+0.78%AUDNZD+0.75%USDZAR+0.68%USDSEK+0.68%NOKJPY-0.67%EURZAR+0.64%EURSEK+0.64%AUDDKK-0.63%AUDCAD-0.62%EURAUD+0.60%GBPAUD+0.55%GBPZAR+0.55%CHFSEK+0.54%AUDSGD-0.50%AUDUSD-0.46%USDTHB+0.45%USDMXN+0.42%GBPTRY+0.41%NZDSGD-0.32%GBPHKD+0.32%EURCHF+0.31%CADCHF+0.30%GBPMXN-0.28%AUDCHF-0.28%GBPCHF+0.27%USDPLN+0.25%AUDNOK+0.24%EURPLN+0.20%USDCHF+0.19%USDILS+0.16%USDSGD+0.16%EURUSD+0.13%USDCAD-0.12%EURSGD+0.12%GBPUSD+0.11%USDTRY+0.11%EURCZK-0.09%NZDMXN-0.08%SGDJPY+0.07%USDCNH+0.05%EURHKD-0.05%EURGBP+0.04%GBPCAD-0.04%USDCOP-0.04%EURCNH+0.04%USDDKK+0.03%GBPSGD+0.03%CHFSGD+0.03%USDHKD+0.01%PLNJPY-0.01%EURDKK-0.01%EURCAD0.00%XPTUSD-4.74%HG1-4.47%GAGUSD-4.15%XAGUSD-4.14%UKOIL+3.54%USOIL+3.11%SUGAR+1.50%XAUUSD-0.98%GAUUSD-0.98%COFFEE-0.76%COTTON+0.66%S1+0.65%BTCUSD-1.21%ETHUSD-1.02%USDTUSD-0.02%XRPUSD-2.60%SOLUSD-1.48%TRXUSDT0.00%ZECUSDT-5.54%DOGEUSD-2.81%XMRUSDT-1.66%LINKUSD-1.09%XLMUSD-1.92%BCHUSDT-10.38%LTCUSD-1.72%UNIUSD-3.29%TONUSD+24.88%HBARUSDT-1.85%SUIUSD-3.41%TAOUSDT-5.10%AAVEUSD-2.76%DOTUSDT-3.34%ICPUSDT-0.79%ONDOUSDT-2.76%WLDUSDT-2.43%ATOMUSDT-3.35%ARBUSDT+1.64%JUPUSDT-2.96%INJUSDT-4.80%STXUSDT-3.07%FETUSDT-3.57%TIAUSDT-0.87%PYTHUSDT+0.14%SEIUSDT-3.91%IMXUSDT-3.85%GRTUSDT-2.94%WIFUSDT-4.40%OPUSDT-3.00%IOTAUSDT-3.76%POLUSDT-5.71%AXSUSDT-2.47%FARTCOINUSDT-2.75%EOSUSDT-0.93%DYDXUSDT-0.80%ORDIUSDT-0.83%GALAUSDT-4.78%NOTUSDT-2.97%RONINUSDT-2.64%
CT

Cullinan Therapeutics, Inc. (CGEM)

NASDAQ • Healthcare

$21.31
-$0.38 (-1.8%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$21.3
Previous Close$21.31
Day Range$21.08 - $21.8
Avg. Volume (3M)757.1K
Market Cap$1.3B
52 Week Range
$5.68$23.19
Next EarningsIn 56 daysNov 5, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$204.6M
EPS (TTM)
-$3.37
ROA (TTM)
-56.27%
Current Ratio
8.42

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+3.8%Q1 2026-$0.77
+10.3%Q2 2026-$0.75
-1.3%Q3 2026-$0.81
Next

Nov 5

in 56 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -1.3%

Cullinan Therapeutics’ loss per share was slightly wider than consensus, with preliminary results for the second fiscal quarter of 2026 reported August 6, 2026 showing EPS of -$0.81 trailed the -$0.80 estimate by -$0.01, while the company continued to operate as a clinical-stage oncology developer across programs such as CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. Net income improved ~23% year over year to about -$53.7 million (up from -$70.1 million a year ago), alongside a ~24% year-over-year improvement in EPS from -$1.07. Operating income for the quarter was about -$57.3 million, and the company generated negative operating cash flow of roughly -$38.2 million, reflecting ongoing spend to advance its pipeline rather than support a marketed product base. For the next period, consensus calls for EPS of -$0.85 on revenue of $2.0 million.

View full earnings history

About Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. is a NASDAQ-listed biotechnology company focused on developing cancer treatments that draw on the immune system. Trading as CGEM, it operates as a clinical-stage drug developer in healthcare, advancing a pipeline of oncology candidates rather than a marketed product portfolio.

Name
Cullinan Therapeutics, Inc.
CEO
Nadim Ahmed
Website
cullinantherapeutics.com
Industry
Healthcare
Year Founded
2016
Employees
109

Today's Snapshot

AI-generated

CGEM opened 1.5% lower at 20.99, while its sector was flat.

Trading Volume

Below 10d avg (656.2K)

180.4K

vs S&P 500 Today

Underperforming Market

-2.14%

Updated: September 10, 2026 at 14:34 UTC

Technical Indicators

4 Buy2 Neutral2 Sell
CGEM’s setup favors the upside on a medium-term basis despite short-term pullback. ADX just above 30 signals a developing trend while several fast oscillators show short-term oversold readings, and MACD is mildly positive, suggesting momentum is turning constructive. The price sits below the 10–20 day averages but remains above the 50–200 day bands, indicating longer-term support is intact even as the market consolidates. Volatility is moderate by ATR and on-balance volume is soft, so momentum may hinge on renewed buying. Technical takeaway: buy — longer-term moving averages and a strengthening trend outweigh short-term weakness.
All signals
  • EMA (5 indicators)$14.87 - $21.60
    Buy
  • RSI (14)49.44
    Neutral
  • Stochastic %K (14, 3, 3)17.72
    Buy
  • MACD Level (12, 26)0.71
    Neutral

Peers & Related Assets

OMEROmeros Corporation
$19.39+1.4%
CBLLCeriBell, Inc.
$24.41+0.4%
VREXVarex Imaging Corporation
$18.5+0.1%
LABStandard BioTools Inc.
$0.73+5.1%
ADCTADC Therapeutics S.A.
$1.22-6.2%
RAPTRAPT Therapeutics, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.